Biogen hopes to bridge the gap with $7.3bn Reata buy
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.